Jörg Assmus

Jörg Assmus

Auto-generated profile, based on publicly available information

Jörg Assmus

Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2012 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
NDNezla S Duric
Nezla S Duric
JAJørg Assmus
Jørg Assmus
DGDoris Gundersen
Doris Gundersen
IEIrene B Elgen
Irene B Elgen
A randomized and controlled clinical study was performed to evaluate the use of neurofeedback (NF) to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. The ADHD population was selected from an outpatient clinic for Child and Adolescent Mental Health in Norway. Ninety-one of the 275 children and adolescents ranging in age from 6 to 18 years (10.5 years) participated in 30 sessions of an intensive NF program. The reinforcement contingency was based on the subjects’ production of cortical beta1 activity (15–18 Hz). The ADHD participants were randomized into three groups, with 30 in the NF group, 31 controls in a group that was given methylphenidate, and 30 in a group that received NF and methylphenidate. ADHD core symptoms were reported by parents using the parent form of the Clinician’s Manual for Assessment by Russell A. Barkley. Ninety-one children and adolescents were effectively randomized by age, sex, intelligence and distribution of ADHD core symptoms. The parents reported significant effects of the treatments, but no significant differences between the treatment groups were observed. NF was as effective as methylphenidate at treating the attentional and hyperactivity symptoms of ADHD, based on parental reports. Current Controlled Trials NCT01252446

11 November 2016 in BMC Neurology
Verified
Journal Article
Open access
PDF file
IBIris Brunner
Iris Brunner
JSJan Sture Skouen
Jan Sture Skouen
HHHåkon Hofstad
Håkon Hofstad
JAJörg Aßmuss
Jörg Aßmuss
FBFrank Becker
Frank Becker
GVGeert Verheyden
Geert Verheyden
Virtual reality (VR) training is thought to improve upper limb (UL) motor function after stroke when utilizing intensive training with many repetitions. The purpose of this study was to compare intensity and content of a VR training intervention to a conventional task-oriented intervention (CT). A random sample of 50 video recordings was analyzed of patients with a broad range of UL motor impairments (mean age 61y, 22 women). Patients took part in the VIRTUES trial and were randomized to either VR or CT and stratified according to severity of paresis. A standardized scoring form was used to analyze intensity, i.e. active use of the affected UL expressed in % of total time, total active time and total duration of a training session in minutes, content of training and feedback. Two raters collected data independently. Linear regression models as well as descriptive and graphical methods were used. Patients in the VR group spent significantly more time actively practicing with an activity rate of 77.6 (8.9) % than patients in the CT 67.3 (13.9) %, (p = .003). This difference was attributed to the subgroup of patients with initially severe paresis (n = 22). While in VR severely impaired patients spent 80.7 % (4.4 %) of the session time actively; they reached 60.6 (12.1) % in CT. VR and CT also differed in terms of tasks and feedback provided. Our results indicate that patients with severely impaired UL motor function spent more time actively in VR training, which may influence recovery. The upcoming results of the VIRTUES trial will show whether this is correlated with an increased effect of VR compared to CT. ClinicalTrials.gov NCT02079103 , February 27, 2014.

1 September 2017 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
RGR.B. Galleberg
R.B. Galleberg
UKU. Knigge
U. Knigge
EJEva Tiensuu Tiensuu Janson
Eva Tiensuu Tiensuu Janson
LVL.W. Vestermark
L.W. Vestermark
SHS.-P. Haugvik
S.-P. Haugvik
HSHalfdan Sorbye
Halfdan Sorbye

15 May 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
NLNicola Logallo
Nicola Logallo
CKChristopher Elnan Kvistad
Christopher Elnan Kvistad
ANAliona Nacu
Aliona Nacu
HNHalvor Naess
Halvor Naess
UWUlrike Waje-Andreassen
Ulrike Waje-Andreassen
LTLars Thomassen
Lars Thomassen
Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke Trial (NOR-TEST) aims to compare efficacy and safety of tenecteplase vs. alteplase.

6 June 2017 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
HBHeiko Bratke
Heiko Bratke
IBIngvild Særvold Bruserud
Ingvild Særvold Bruserud
BBBente Brannsether
Bente Brannsether
JAJörg Aßmus
Jörg Aßmus
RBRobert Bjerknes
Robert Bjerknes
PJPétur B. Júlíusson
Pétur B. Júlíusson
Research studies show conflicting results regarding the association between menarche and body weight. The purpose of the present study was to investigate if anthropometric indicators of body composition, body mass index (BMI), waist circumference (WC), triceps (TSF) and subscapular skinfold (SSF) thicknesses, were differentially associated with age at menarche in Norwegian girls. The association between menarche and BMI, WC, TSF and SSF was investigated in 1481 girls aged 8–15.5 years, and in a subgroup of 181 girls with menarche during the 12 months prior to examination. Anthropometric measures were categorized as low (< −1SDS), average (−1 ≤ SDS ≤ +1) or high (> 1SDS), and menarche according to this classification was analysed with Kaplan-Meier curves and unadjusted and adjusted Cox regression. The median age at menarche in the total sample was 13.1 years. In the unadjusted models, low categories of all traits were associated with later menarche, and high categories with earlier menarche. When adjusted for other covariates, earlier menarche was only related with a high BMI (Hazard Ratio 1.41, 95% confidence interval (CI) 1.07, 1.85), and later menarche with a low BMI (HR 0.53, 95%CI 0.38, 0.75) and low SSF (HR 0.54, 95%CI 0.39, 0.75). In girls with recent menarche, early menarche was significantly associated with a high BMI in the final model (HR 1.79, 95%CI 1.23, 2.62). The timing of menarche was associated with the BMI, WC, TSF and SSF, but more strongly so with the BMI. These associations may be related to a common tempo of growth, as the mean age at menarche has remained stable during the last decades during a time period while the prevalence of overweight and obesity has increased significantly.

16 May 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MJMelissa Davidsen Jørstad
Melissa Davidsen Jørstad
ARAnne Margarita Dyrhol Riise
Anne Margarita Dyrhol Riise
JAJörg Aßmus
Jörg Aßmus
MMMsafiri Marijani
Msafiri Marijani
LSLisbet Sviland
Lisbet Sviland
TMTehmina Mustafa
Tehmina Mustafa
Diagnosing extrapulmonary tuberculosis (EPTB) is challenging and many patients are initiated on empirical anti-TB treatment without a laboratory confirmed diagnosis. Monitoring treatment response is thus important to ensure correct diagnosis and proper disease management. The definition of satisfactory response to treatment in EPTB remains unclear. The objectives of this study were to describe the clinical presentation of EPTB and the effect of treatment on clinical parameters. Further, to assess if simple clinical parameters, without laboratory data, could evaluate treatment response. Prospective cohort study of presumptive EPTB patients at Mnazi Mmoja Hospital, Zanzibar. By using a composite reference standard, patients were categorized as TB or non-TB cases. The TB patients were followed during anti-TB treatment. There were 64 TB and 62 non-TB cases. The frequency of symptoms at baseline were comparable in TB and non-TB patients, with lymphadenitis and pleuritis as the most common manifestations. Among TB cases, there was a trend towards regression of lymphadenopathy after 2 months, and at treatment completion 24/28 (86%) cases showed full regression. Weight gain ≥5% was reported in 36/49 (73%) of the TB patients at 2 months and in 38/46 (83%) at treatment completion. After 2 months of treatment, a combination of clinical parameters; improvement of symptoms (50/50), ≥5% weight gain (36/49) and regression of physical signs (45/49) correlated with the treatment response. An algorithm including only simple clinical parameters could be used as an easy tool to assess treatment responses in low-resource settings. However, this needs to be tested on a larger sample size.